Crispr Therapeutics AG (CRSP) is experiencing a notable decline in stock value as investor sentiment shifts amid recent developments.
Crispr Therapeutics AG's stock is sliding today, down 2.88% to close at CA$51.85. This decline comes after mixed reactions from investors regarding recent news and ongoing market conditions affecting the biotech sector.
Investor takeaway: The drop in Crispr Therapeutics' stock raises concerns about its future growth potential, especially as competitors like Roche report positive clinical data that could overshadow Crispr's advancements.
Advertisement
Crispr Therapeutics AG
CRSP.US
CRSP.US
Crispr Therapeutics AG
WealthAwesomeMarket cap
$5.16B
52W high
$75.06
52W low
$44.12
1W change
-3.68%
Beta
1.76
Analyst Price Targets
Based on 22 analysts covering CRSP · as of Oct 12, 2026
Wall Street analysts forecast CRSP stock price to rise 63.9% over the next 12 months.
Consensus
Buy3.95 / 5.00
Avg. Target
C$87.50
+63.9% Upside
Previously C$87.56 on Oct 5, 2026
Current Price
C$53.39
Last close
Analyst Breakdown (22 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRSP's historical volatility
30-Day Vol
50.3%
Annualized
90-Day Vol
52.6%
Annualized
Trend (90d)
+39.7%
Annualized drift
90d Mean
C$61.53
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$55.98 | C$47.06 – C$66.58 |
| 60 trading days | C$58.69 | C$45.92 – C$75.01 |
| 90 trading days | C$61.53 | C$45.56 – C$83.10 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Stock Down 2.88%
Crispr Therapeutics AG's market cap now stands at approximately CA$5.16 billion.
Bull case
Crispr Therapeutics has a strong pipeline of gene-editing therapies. One highlight is the upcoming presentation of late-breaking data from its Phase 1b trial targeting severe hypertriglyceridemia, which could spark renewed interest from investors.
Bear case
The recent drop in stock price reflects investor skepticism about Crispr's ability to compete effectively in a rapidly evolving biotech landscape. Competitors are achieving significant milestones, raising questions about Crispr's market position.
Advertisement
Market Reaction to Recent Developments
Crispr Therapeutics' stock slide coincides with a wave of positive news from competitors, particularly Roche, which announced promising results for its investigational eye drug. As investors weigh the implications of these developments, Crispr's ability to maintain investor confidence is being tested.
Pipeline Prospects and Challenges
While Crispr Therapeutics has an ambitious pipeline, including upcoming presentations at major conferences, the recent stock decline highlights the challenges it faces in a competitive market. Investors are closely monitoring the company's progress and upcoming data releases to gauge its potential for recovery.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
